Lysine acetylation regulates Bruton's tyrosine kinase in B cell activation

Journal of Immunology

Volumn 184, Issue 1, 2010, Pages 244-254

  Liu, Zhijian ^a,c,d   Mai, Antonello ^d,e   Sun, Jian ^a,b  

^a SHANGHAI UNIVERSITY OF MEDICINE AND HEALTH SCIENCES   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; BRUTON TYROSINE KINASE; HISTONE ACETYLTRANSFERASE; LYSINE; MESSENGER RNA; PROTEIN P300; AGAMMAGLOBULINAEMIA TYROSINE KINASE; ENZYME INHIBITOR; HISTONE; HISTONE ACETYLTRANSFERASE PCAF; P300-CBP-ASSOCIATED FACTOR; PROTEIN TYROSINE KINASE;

ACETYLATION; ARTICLE; B LYMPHOCYTE ACTIVATION; CROSS LINKING; ENZYME ACTIVITY; ENZYME REGULATION; GENE LOCUS; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; ANIMAL; B LYMPHOCYTE; BIOSYNTHESIS; C57BL MOUSE; DNA MICROARRAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ACETYLATION; ANIMALS; B-LYMPHOCYTES; BLOTTING, WESTERN; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HISTONES; LYMPHOCYTE ACTIVATION; LYSINE; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; P300-CBP TRANSCRIPTION FACTORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 73949137382     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902324     Document Type: Article

References (44)

1. Khan, W. N. 2001. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase. Immunol. Res. 23: 147-156.
2. Satterthwaite, A. B., and O. N. Witte. 2000. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol. Rev. 175: 120-127.
3. Rawlings, D. J., and O. N. Witte. 1994. Bruton's tyrosine kinase is a key regulator in B-cell development. Immunol. Rev. 138: 105-119.
4. Tsukada, S., D. J. Rawlings, and O. N. Witte. 1994. Role of Bruton's tyrosine kinase in immunodeficiency. Curr. Opin. Immunol. 6: 623-630.
5. Lindvall, J. M., K. E. Blomberg, J. Väliaho, L. Vargas, J. E. Heinonen, A. Berglöf, A. J. Mohamed, B. F. Nore, M. Vihinen, and C. I. Smith. 2005. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol. Rev. 203: 200-215.
6. Khan, W. N., F. W. Alt, R. M. Gerstein, B. A. Malynn, I. Larsson, G. Rathbun, L. Davidson, S. Müller, A. B. Kantor, L. A. Herzenberg, et al. 1995. Defective B cell development and function in Btk-deficient mice. Immunity 3: 283-299.
7. Rawlings, D. J., A. M. Scharenberg, H. Park, M. I. Wahl, S. Lin, R. M. Kato, A. C. Fluckiger, O. N. Witte, and J. P. Kinet. 1996. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science 271: 822-825.
8. Himmelmann, A., C. Thevenin, K. Harrison, and J. H. Kehrl. 1996. Analysis of the Bruton's tyrosine kinase gene promoter reveals critical PU.1 and SP1 sites. Blood 87: 1036-1044. (Pubitemid 26049874)
9. Webb, C. F., Y. Yamashita, N. Ayers, S. Evetts, Y. Paulin, M. E. Conley, and E. A. Smith. 2000. The transcription factor Bright associates with Bruton's tyrosine kinase, the defective protein in immunodeficiency disease. J. Immunol. 165: 6956-6965.
10. Brunner, C., and T. Wirth. 2006. Btk expression is controlled by Oct and BOB.1/OBF.1. Nucleic Acids Res. 34: 1807-1815.
11. Yu, L., A. J. Mohamed, O. E. Simonson, L. Vargas, K. E. Blomberg, B. Björkstrand, H. J. Arteaga, B. F. Nore, and C. I. Smith. 2008. Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB. Blood 111: 4617-4626.
12. Müller, S., A. Maas, T. C. Islam, P. Sideras, G. Suske, S. Philipsen, K. G. Xanthopoulos, R. W. Hendriks, and C. I. Smith. 1999. Synergistic activation of the human Btk promoter by transcription factors Sp1/3 and PU.1. Biochem. Biophys. Res. Commun. 259: 364-369.
13. Jenuwein, T., and C. D. Allis. 2001. Translating the histone code. Science 293: 1074-1080.
14. Sterner, D. E., and S. L. Berger. 2000. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 64: 435-459.
15. Hassig, C. A., and S. L. Schreiber. 1997. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr. Opin. Chem. Biol. 1: 300-308.
16. Kouzarides, T. 2007. Chromatin modifications and their function. Cell 128: 693-705.
17. Glozak, M. A., N. Sengupta, X. Zhang, and E. Seto. 2005. Acetylation and deacetylation of non-histone proteins. Gene 363: 15-23.
18. Cheung, W. L., S. D. Briggs, and C. D. Allis. 2000. Acetylation and chromosomal functions. Curr. Opin. Cell Biol. 12: 326-333.
19. Gu, W., and R. G. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606.
20. Hubbert, C., A. Guardiola, R. Shao, Y. Kawaguchi, A. Ito, A. Nixon, M. Yoshida, X. F. Wang, and T. P. Yao. 2002. HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458.
21. Allis, C. D., S. L. Berger, J. Cote, S. Dent, T. Jenuwien, T. Kouzarides, L. Pillus, D. Reinberg, Y. Shi, R. Shiekhattar, et al. 2007. New nomenclature for chromatin-modifying enzymes. Cell 131: 633-636.
22. Yang, X. J., and E. Seto. 2008. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol. Cell 31: 449-461.
23. Avila, A. M., B. G. Burnett, A. A. Taye, F. Gabanella, M. A. Knight, P. Hartenstein, Z. Cizman, N. A. Di Prospero, L. Pellizzoni, K. H. Fischbeck, and C. J. Sumner. 2007. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 117: 659-671.
24. Gray, S. G., T. Yakovleva, W. Hartmann, M. Tally, G. Bakalkin, and T. J. Ekström. 1999. IGF-II enhances trichostatin A-induced TGFbeta1 and p21 (Waf1,Cip1, sdi1) expression in Hep3B cells. Exp. Cell Res. 253: 618-628.
25. Sandoval, J., J. L. Rodríguez, G. Tur, G. Serviddio, J. Pereda, A. Boukaba, J. Sastre, L. Torres, L. Franco, and G. López-Rodas. 2004. RNAPol-ChIP: a novel application of chromatin immunoprecipitation to the analysis of realtime gene transcription. Nucleic Acids Res. 32: e88.
26. Hess-Stumpp, H., T. U. Bracker, D. Henderson, and O. Politz. 2007. MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int. J. Biochem. Cell Biol. 39: 1388-1405.
27. Mai, A., S. Massa, R. Pezzi, S. Simeoni, D. Rotili, A. Nebbioso, A. Scognamiglio, L. Altucci, P. Loidl, and G. Brosch. 2005. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl) pyrrolyl hydroxyamides. J. Med. Chem. 48: 3344-3353.
28. Inoue, S., A. Mai, M. J. Dyer, and G. M. Cohen. 2006. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 66: 6785-6792.
29. Hu, E., E. Dul, C. M. Sung, Z. Chen, R. Kirkpatrick, G. F. Zhang, K. Johanson, R. Liu, A. Lago, G. Hofmann, et al. 2003. Identification of novel isoformselective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307: 720-728.
30. Marcu, M. G., Y. J. Jung, S. Lee, E. J. Chung, M. J. Lee, J. Trepel, and L. Neckers. 2006. Curcumin is an inhibitor of p300 histone acetylatransferase. Med. Chem. 2: 169-174.
31. Morimoto, T., Y. Sunagawa, T. Kawamura, T. Takaya, H. Wada, A. Nagasawa, M. Komeda, M. Fujita, A. Shimatsu, T. Kita, and K. Hasegawa. 2008. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J. Clin. Invest. 118: 868-878.
32. Baba, Y., S. Hashimoto, M. Matsushita, D. Watanabe, T. Kishimoto, T. Kurosaki, and S. Tsukada. 2001. BLNK mediates Syk-dependent Btk activation. Proc. Natl. Acad. Sci. USA 98: 2582-2586.
33. McMurry, M. T., and M. S. Krangel. 2000. A role for histone acetylation in the developmental regulation of VDJ recombination. Science 287: 495-498.
34. Nambu, Y., M. Sugai, H. Gonda, C. G. Lee, T. Katakai, Y. Agata, Y. Yokota, and A. Shimizu. 2003. Transcription-coupled events associating with immunoglobulin switch region chromatin. Science 302: 2137-2140.
35. Wang, L., N. Whang, R. Wuerffel, and A. L. Kenter. 2006. AID-dependent histone acetylation is detected in immunoglobulin S regions. J. Exp. Med. 203: 215-226.
36. Woo, C. J., A. Martin, and M. D. Scharff. 2003. Induction of somatic hypermutation is associated with modifications in immunoglobulin variable region chromatin. Immunity 19: 479-489.
37. Xu, W., T. Fukuyama, P. A. Ney, D. Wang, J. Rehg, K. Boyd, J. M. van Deursen, and P. K. Brindle. 2006. Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells. Blood 107: 4407-4416.
38. Lin, H. Y., C. S. Chen, S. P. Lin, J. R. Weng, and C. S. Chen. 2006. Targeting histone deacetylase in cancer therapy. Med. Res. Rev. 26: 397-413.
39. Chittur, S. V., N. Sangster-Guity, and P. J. McCormick. 2008. Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism. BMC Genomics 9: 507.
40. Drummond, D. C., C. O. Noble, D. B. Kirpotin, Z. Guo, G. K. Scott, and C. C. Benz. 2005. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45: 495-528.
41. Motta, M. C., N. Divecha, M. Lemieux, C. Kamel, D. Chen, W. Gu, Y. Bultsma, M. McBurney, and L. Guarente. 2004. Mammalian SIRT1 represses forkhead transcription factors. Cell 116: 551-563.
42. Tang, Y., J. Luo, W. Zhang, and W. Gu. 2006. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell 24: 827-839.
43. Choudhary, C., C. Kumar, F. Gnad, M. L. Nielsen, M. Rehman, T. C. Walther, J. V. Olsen, and M. Mann. 2009. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840.
44. Tang, X., J. S. Gao, Y. J. Guan, K. E. McLane, Z. L. Yuan, B. Ramratnam, and Y. E. Chin. 2007. Acetylation-dependent signal transduction for type I interferon receptor. Cell 131: 93-105.